Loading tape…Loading tape…
AMGN
AMGN
AMGN
AMGN NASDAQ
Amgen Inc announced via prnewswire.com that AMGEN'S REPATHA® REDUCES RISK OF DEATH IN PATIENTS AT HIGH RISK FOR A FIRST HEART ATTACK OR STROKE. This development links to a company supported by full-year revenue of $36.74B and a market cap of approximately $236.46B. Furthermore, Amgen maintains an EPS TTM of 16.19, a P/E ratio of 27.01, and a free cash flow yield of 4.30%.
Based on prnewswire.comAMGEN'S REPATHA® REDUCES RISK OF DEATH IN PATIENTS AT HIGH RISK FOR A FIRST HEART ATTACK OR STROKE
One Of Amgen's Biggest Moneymakers Cuts The Risk Of Dying By 20%
Amgen vs. Axsome Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Blue Edge Capital LLC Purchases New Position in Amgen Inc. $AMGN
AZN/AMGN's Tezspire Hits Primary Goal in Eosinophilic Esophagitis Study
Arini Capital Management Ltd Buys Shares of 20,000 Amgen Inc. $AMGN
Revenue & Net Income (5Y)
EPS & Growth (5Y)
Free Cash Flow (5Y)
Capital Returns
Operating & Net Margin (5Y)
CapEx vs. Free Cash Flow (5Y)
Capital Allocation (5Y)
R&D and SG&A Intensity (5Y)
EBITDA (5Y)
Cost of Revenue (5Y)
Market Cap (5Y)
Ask Stonks with professional market data, charts beside chat, and your portfolio context.
Tape shows delayed public market data. Not investment advice.